CYP2C19与CYP2D6慢代谢及中间代谢状态与抗抑郁药和抗精神病药暴露的系统综述与Meta分析
该系统综述与Meta分析纳入94项研究共8379名个体,量化了CYP2C19和CYP2D6基因型对应的慢代谢、中间代谢与正常代谢者之间抗精神病药和抗抑郁药暴露的差异。最显著的差异见于阿立哌唑、氟哌啶醇、利培酮、艾司西酞普兰和舍曲林,暴露差异足以支持基于基因型的剂量推荐。
要点
- CYP2D6慢代谢+中间代谢者阿立哌唑暴露为正常代谢者的1.48倍(95%CI 1.41-1.57)。
- CYP2C19慢代谢者艾司西酞普兰暴露为正常代谢者的2.63倍(95%CI 2.40-2.89)。
- 部分药物暴露差异微小、不明确或基于不足3项独立研究。
核心结论
- CYP2C19/CYP2D6基因型与多种精神药物血药浓度的关联被足够精确地量化,可作为基于基因型剂量推荐的科学基础。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Clinicaltrialsregister.eu、ClinicalTrials.gov、国际临床试验注册平台和CENTRAL数据库1990年1月1日至2020年6月30日文献,无语言限制。
- 纳入标准包括:进行了适当的CYP2C19或CYP2D6基因分型、可基于基因型分类为正常代谢、中间代谢和慢代谢、每个代谢类别至少有3名患者。
- 采用固定效应模型合并效应量,遵循MOOSE指南进行数据提取和质量评价。
主要发现
- 基于94项独特研究和8379名独特个体的数据。
- 阿立哌唑:CYP2D6慢代谢+中间代谢 vs 正常代谢的均值比(RoM)为1.48(95%CI 1.41-1.57;12项研究;1038名患者)。
- 氟哌啶醇乳酸酯:CYP2D6慢代谢 vs 正常代谢的RoM为1.68(95%CI 1.40-2.02;9项研究;423名患者)。
- 利培酮:CYP2D6慢代谢+中间代谢 vs 正常代谢的RoM为1.36(95%CI 1.28-1.44;23项研究;1492名患者)。
- 艾司西酞普兰草酸盐:CYP2C19慢代谢 vs 正常代谢的RoM为2.63(95%CI 2.40-2.89;4项研究;1262名患者)。
关键数值与推荐
- 药物暴露测量指标为剂量归一化的血浆浓度-时间曲线下面积、剂量归一化的稳态血浆浓度或表观总清除率的倒数。
- 均值比(RoM)计算方式为慢代谢、中间代谢或慢代谢+中间代谢合并类别的平均药物暴露除以正常代谢类别的平均药物暴露。
临床怎么用
- 对于阿立哌唑、氟哌啶醇、利培酮、艾司西酞普兰和舍曲林,可依据CYP2D6/CYP2C19基因型调整剂量以优化个体化治疗。
- 对于其他提及药物,基因型指导剂量调整的证据尚不充分或差异不明确,需结合临床判断。
局限性
- 部分药物的暴露差异微小、不明确或基于不足3项独立研究,结论可靠性有限。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Precise estimation of the drug metabolism capacity for individual patients is crucial for adequate dose personalization. OBJECTIVE: To quantify the difference in the antipsychotic and antidepressant exposure among patients with genetically associated CYP2C19 and CYP2D6 poor (PM), intermediate (IM), and normal (NM) metabolizers. DATA SOURCES: PubMed, Clinicaltrialsregister.eu, ClinicalTrials.gov, International Clinical Trials Registry Platform, and CENTRAL databases were screened for studies from January 1, 1990, to June 30, 2020, with no language restrictions. STUDY SELECTION: Two independent reviewers performed study screening and assessed the following inclusion criteria: (1) appropriate CYP2C19 or CYP2D6 genotyping was performed, (2) genotype-based classification into CYP2C19 or CYP2D6 NM, IM, and PM categories was possible, and (3) 3 patients per metabolizer category were available. DATA EXTRACTION AND SYNTHESIS: The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were followed for extracting data and quality, validity, and risk of bias assessments. A fixed-effects model was used for pooling the effect sizes of the included studies. MAIN OUTCOMES AND MEASURES: Drug exposure was measured as (1) dose-normalized area under the plasma level (time) curve, (2) dose-normalized steady-state plasma level, or (3) reciprocal apparent total drug clearance. The ratio of means (RoM) was calculated by dividing the mean drug exposure for PM, IM, or pooled PM plus IM categories by the mean drug exposure for the NM category. RESULTS: Based on the data derived from 94 unique studies and 8379 unique individuals, the most profound differences were observed in the patients treated with aripiprazole (CYP2D6 PM plus IM vs NM RoM, 1.48; 95% CI, 1.41-1.57; 12 studies; 1038 patients), haloperidol lactate (CYP2D6 PM vs NM RoM, 1.68; 95% CI, 1.40-2.02; 9 studies; 423 patients), risperidone (CYP2D6 PM plus IM vs NM RoM, 1.36; 95% CI, 1.28-1.44; 23 studies; 1492 patients), escitalopram oxalate (CYP2C19 PM vs NM, RoM, 2.63; 95% CI, 2.40-2.89; 4 studies; 1262 patients), and sertraline hydrochloride (CYP2C19 IM vs NM RoM, 1.38; 95% CI, 1.27-1.51; 3 studies; 917 patients). Exposure differences were also observed for clozapine, quetiapine fumarate, amitriptyline hydrochloride, mirtazapine, nortriptyline hydrochloride, fluoxetine hydrochloride, fluvoxamine maleate, paroxetine hydrochloride, and venlafaxine hydrochloride; however, these differences were marginal, ambiguous, or based on less than 3 independent studies. CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, the association between CYP2C19/CYP2D6 genotype and drug levels of several psychiatric drugs was quantified with sufficient precision as to be useful as a scientific foundation for CYP2D6/CYP2C19 genotype-based dosing recommendations.
引用
- Milosavljevic F, Bukvic N, Pavlovic Z, et al. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021. PMID: 33237321. doi:10.1001/jamapsychiatry.2020.3643
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。